Therapy-related myeloid neoplasms

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 672-680

  Leone, Giuseppe ^a   Fianchi, Luana ^a   Voso, Maria T ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

acute myeloid leukemia; MDS; secondary leukemia; therapy related myeloid neoplasms

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; IDARUBICIN; INTERCALATING AGENT; LENALIDOMIDE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROCARBAZINE; RAZOXANE; RETINOIC ACID; RITUXIMAB; TAXANE DERIVATIVE; TENIPOSIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CANCER SUSCEPTIBILITY; CARDIOTOXICITY; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; COPY NUMBER VARIATION; DRUG MECHANISM; FOLLOW UP; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATHOGENESIS; PELVIS TUMOR; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SOLID TUMOR; TESTIS CANCER; THERAPY RELATED MYELOID NEOPLASM; WORLD HEALTH ORGANIZATION;

HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASMS, SECOND PRIMARY;

EID: 80054092753     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834bcc2a     Document Type: Review

References (49)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
2. Stoddart A, Mcnerney M, Bartom, et al. Genetic pathways leading to therapyrelated myeloid neoplasms. Mediterranean J Hematol Infect Dis, North America, 3 May. 2011. http://www.mjhid.org/article/view/8226.
3. Miesner M, Haferlach C, Bacher U, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as 'AML not otherwise specified' (AML-NOS) or 'AML with myelodysplasia-related changes' (AML-MRC). Blood 2010; 116:2742-2751.
4. Kayser S, Dö hner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117:2137-2145.
5. Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008; 112:3383-3390.
6. Itzhar N, Dessen P, Toujani S, et al. Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH. PLoS One 2011; 6:e16623.
7. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29:573-578.
8. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-1093. (Pubitemid 47014426)
9. Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009; 113:5575-5582.
10. Hasan SK, Buttari F, Ottone T, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. Neurology 2011; 76:1059-1065.
11. Hanzis C, Ojha RP, Hunter Z, et al. Associated malignancies in patients with Waldenströ m's macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk 2011; 11:88-92.
12. Greco M, D'Alò F, Scardocci A, et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis 2010; 45:181-185.
13. Slovak ML, Bedell V, Lew D, et al. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat 2010; 119:391-398.
14. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009; 27:791-798.
15. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102:43-52. (Pubitemid 36759634)
16. Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24:371-382.
17. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6- mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009; 113:6077-6084.
18. Stanulla M, Schaeffeler E, Mö ricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Mü nster protocols. Blood 2009; 114:1314-1318.
19. Renard M, Suciu S, Bertrand Y, et al., on behalf of EORTC Children Leukaemia Group (CLG). Second neoplasm in children treated in EORTC 58881. trial for acute lymphoblastic malignancies: low incidence of CNS tumours. Pediatr Blood Cancer 2011; 15:119-125.
20. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11:950-961.
21. VroomanLM, Neuberg DS, Stevenson KE, et al. The lowincidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011; 47:1373-1379.
22. Montesinos P, Gonzá lez JD, Gonzá lez J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with alltrans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol 2010; 28:3872-3879.
23. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007; 92: 1389-1398. (Pubitemid 350144157)
24. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27:4548-4554.
25. Scholz M, Engert A, Franklin J, et al. Impact of first-and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL-experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Ann Oncol 2011; 22:681-688.
26. Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011; 29:814-824.
27. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27:250-255.
28. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010; 24:2056-2062.
29. Tam CS, O'Brien S, Wierda W, et al. Long term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975-980.
30. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progressionfree survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011; 29:1349-1355.
31. Gruschkus SK, Lairson D, Dunn JK, et al. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer 2010; 116: 5279-5289.
32. Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23:2222-2232.
33. Goswami RS, Barth D, Masih-Khan E, et al. Characteristics of patients presenting with secondary myelodysplastic syndrome during treatment with lenalidomide for relapsed/refractory multiple myeloma: 5q deletions can be observed. American Society of Hematol, 52nd Annual Meeting, abstract 1876.
34. Azim AH, de Azambuja E, Colozza M, et al. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 2011. [Epub ahead of print]
35. Burnell M, Levine MN, Chapman JA, et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. Clin Oncol 2010; 28:77-82.
36. Martin MG, Welch JS, Luo J, et al. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat 2009; 118:593-598.
37. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27:1177-1183.
38. Cluze C, Delafosse P, Seigneurin A, Colonna M. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. Eur J Cancer Prev 2009; 18:343-348.
39. Beadle G, Baade P, Fritschi L. Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Ann Oncol 2009; 20:103-109.
40. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196-205.
41. Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28:2874-2880.
42. Zhang W, Becciolini A, Biggeri A, et al. Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy. Breast Cancer Res 2011; 13:R38.
43. Wright JD, St. Clair CM, Deutsch I, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010; 2486-2492.
44. Howard R, Gilbert E, Lynch CF, et al. Risk of leukemia among survivors of testicular cancer: a population-based study of 42, 722 patients. Ann Epidemiol 2008; 18:416-421. (Pubitemid 351728082)
45. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and metaanalysis. Thyroid 2009; 19:451-457.
46. Iyer NG, Morris LGT, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 1-8.
47. Maule M, Scé lo G, Pastore G, et al. Second malignancies after childhood noncentral nervous systemsolid cancer: results from 13 cancer registries. Int J Cancer 2011. [Epub ahead of print]
48. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27:2356-2362.
49. Breslow NE, Lange JM, Friedman DL, et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer 2010; 127:657-666.